Brief: Mabion Signs $372 Commercial Scale Production Deal With Novavax

Mabion SA

08/10/2021 07:41

Oct 8 (Reuters) - Mabion SA  MABP.WA :
    * SAYS SIGNS COMMERCIAL SCALE PRODUCTION DEAL WITH NOVOVAX
    * SAYS TOTAL VALUE OF AGREEMENT IS $372 MLN
    * SAYS DEAL TO RUN FROM 2022-2025
    * SAYS WILL PRODUCE ANTIGENE FOR COVID-19 VACCINE
    * SAYS DEAL IS UNCONDITIONAL AND IS NOT DEPENDENT ON VACCINE
REGISTRATION PROCEDURES
    * SAYS DEAL IS TO BE CARRIED OUT AND SETTLED ON A PER BATCH
BASIS
FOR AN AGREED PRICE PER SERIES
    * SAYS COMMERCIAL SCALE MANUFACTURING IN GMP STANDARD TO
START IN
DEC

Source text for Eikon:  ID:nEM9xsX7wa 
Further company coverage:  MABP.WA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))